Course Content
Targeted Drug Delivery Systems for Image-Guided Cancer Treatment
0/2
Abstract
Targeted Drug Delivery Systems for Image-Guided Cancer Treatment
26:05
New Approaches to Imaging Proteases with Nanomaterials
0/2
Abstract
New Approaches to Imaging Proteases with Nanomaterials
00:00
MINT YIA Award Finalist: Copper Nanostructures: A New Frontier in Cancer Diagnosis and Treatment
0/1
MINT YIA Award Finalist: Copper Nanostructures: A New Frontier in Cancer Diagnosis and Treatment
00:00
MINT YIA Award Finalist: Immune Checkpoint Targeted Nanobubbles for Multimodal Molecular Imaging of Tumor-Specific Expression of PD-L1 in Triple Negative Breast Cancer In vivo
0/1
MINT YIA Award Finalist: Immune Checkpoint Targeted Nanobubbles for Multimodal Molecular Imaging of Tumor-Specific Expression of PD-L1 in Triple Negative Breast Cancer In vivo
00:00
MINT YIA Award Finalist: Ultrasmall iron-gallic acid coordination polymer nanoparticles for scavenging ROS and suppressing inflammation in tauopathy-induced Alzheimer’s disease
0/1
MINT YIA Award Finalist: Ultrasmall iron-gallic acid coordination polymer nanoparticles for scavenging ROS and suppressing inflammation in tauopathy-induced Alzheimer’s disease
00:00
MINT YIA Award Finalist: Modular Polymeric Micelle Platform for Multimodal Image-Guided Cancer Nanomedicine
0/1
MINT YIA Award Finalist: Modular Polymeric Micelle Platform for Multimodal Image-Guided Cancer Nanomedicine
00:00
Molecular Imaging in Nanotechnology and Theranostics (MINT) Workshop

Talk Summary:

The advancement of targeted drug delivery faces significant challenges for clinical translation, such as issues related to poor solubility, non-specific distribution, and limited bioavailability of cancer theranostics. Notably, promising developments in near-infrared (NIR) imaging, particularly those centered around Indocyanine Green (ICG), hold the potential for intraoperative tumor targeting. However, the field of medical imaging grapples with two persistent challenges: 1) non-targeted uptake and 2) incomplete elimination of imaging agents. In response to these issues, we focus on the creation of targeted NIR-I/II fluorescence agents possessing optimized physicochemical properties. These innovative compounds encompass zwitterionic organic nanocarriers, such as the noteworthy Harvard-Dots (H-Dots). Importantly, these agents can be administered systemically, circumventing non-specific tissue uptake and achieving exclusive elimination through the urinary system.

H-Dots not only enable the precise determination of surgical margins through NIR image-guided procedures but also serve as effective carriers for targeted anticancer drug delivery. Their unique characteristics result in reduced uptake by the immune system, heightened selectivity for tumors, and enhanced tumor suppression compared to conventional free drugs. Consequently, these H-Dots represent a highly promising theranostic nanoplatform. This research not only signifies a significant step forward in the realm of translational research but also marks a pivotal development in the field of fluorescence image-guided cancer surgery and treatment. Furthermore, it paves the way for the creation of renal-clearable, tissue-specific NIR contrast agents, holding great promise for future advancements in image-guided cancer surgery and, ultimately, improved patient outcomes.

References:

  1. Kang H, Gravier J, Bao K, Wada H, Lee JH, Baek Y, El Fakhri G, Gioux S, Rubin BP, Coll JL, Choi HS. Renal clearable organic nanocarriers for bioimaging and drug delivery. Adv Mater. 2016; 28(37):8162-8.
  2. Kang H, Han M, Xue J, Baek Y, Chang J, Hu S, Nam H, Jo MJ, El Fakhri G, Hutchens M, Choi HS, Kim J. Renal clearable nanochelators for iron overload therapy. Nat Commun. 2019;10(1):5134.
  3. Kang H, Stiles WR, Baek Y, Nomura S, Bao K, Shuang H, Park GK, Jo MJ, I H, Coll JL, Rubin BP, Choi HS. Renal clearable theranostic nanoplatforms for gastrointestinal stromal tumors. Adv Mater. 2020;32(6):1905899.
  4. Kang H, Rho S, Stiles WR, Hu S, Baek Y, Hwang DW, Kashiwagi S, Kim MS, Choi HS. Size-dependent EPR effect of polymeric nanoparticles on tumor targeting. Adv Healthc Mater. 2020;9(1):e1901223.
  5. Park SH, Kim RS, Stiles WR, Jo M, Zeng L, Rho S, Baek Y, Kim J, Kim MS, Kang H, Choi HS. Injectable thermosensitive hydrogels for a sustained release of iron nanochelators. Adv Sci. 2022;9(15):2200872. PMCID: PMC9130884.
  6. Yin X, Cui Y, Kim RS, Stiles WR, Park SH, Wang H, Ma L, Chen L, Baek Y, Kashiwagi S, Bao K, Ulumben A, Fukuda T, Kang H, Choi HS. Image-guided drug delivery of nanotheranostics for targeted lung cancer therapy. Theranostics 2022;12(9):4147-62.
  7. Park HS, Yokomizo S, Wang H, Manganiello S, Monaco H, McDonnell R, Kim HJ, Rho J, Ahn S, Jung H, Kang H, Bao K, Kashiwagi S, Choi HS. Bifunctional tumor-targeted bioprobe for phototheranosis. Biomater Res. 2024;28:0002.

Presenter Biography:
Dr. Hak Soo Choi is a Professor of Radiology at Harvard Medical School, a faculty member of Dana Farber/Harvard Cancer Center, and Director of the Bioengineering & Nanomedicine Program of Mass General Hospital. Dr. Choi received a Ph.D. degree in Nanomedicine from Japan Advanced Science and Technology in 2004. After postdoc training in the field of Gene and Drug Delivery, he extended his research into Molecular Cancer Imaging at Harvard. Since 2008, Dr. Choi’s laboratory has been at the forefront of pioneering research, with a primary focus on developing targeted contrast agents for tissue-specific imaging. These agents play a crucial role in diagnosing and treating human diseases by enabling the visualization of target tissues through “Structure-Inherent Targeting,” while minimizing nonspecific uptake in normal tissues. Dr. Choi’s groundbreaking work has resulted in the publication of over 200 papers and his expertise in nanomedicine and molecular imaging holds great promise for advancing the field of cancer diagnostics and therapeutics.

Previous
Next
0% Complete